Advancing the prevention and treatment of HIV in children: priorities for research and development

Martina Penazzato; Claire L Townsend; Nadia A Sam-Agudu; Theodore D Ruel; Moherndran Archary; Adrie Bekker; Tim R Cressey; Angela Colbers; Nandita Sugandhi; Pablo Rojo; Natella Rakhmanina; Melynda Watkins; Lisa Frigati; Irene Mukui; Asma Hafiz; Marissa Vicari; Edmund V Capparelli; Elaine J Abrams; PADO-HIV 5 participants

doi:10.1016/S2352-3018(22)00101-1

Advancing the prevention and treatment of HIV in children: priorities for research and development

Lancet HIV. 2022 Sep;9(9):e658-e666. doi: 10.1016/S2352-3018(22)00101-1. Epub 2022 Jul 18.

Authors

Martina Penazzato¹, Claire L Townsend², Nadia A Sam-Agudu³, Theodore D Ruel⁴, Moherndran Archary⁵, Adrie Bekker⁶, Tim R Cressey⁷, Angela Colbers⁸, Nandita Sugandhi⁹, Pablo Rojo¹⁰, Natella Rakhmanina¹¹, Melynda Watkins¹², Lisa Frigati¹³, Irene Mukui¹⁴, Asma Hafiz², Marissa Vicari¹⁵, Edmund V Capparelli¹⁶, Elaine J Abrams¹⁷; PADO-HIV 5 participants

Collaborators

PADO-HIV 5 participants:
Elaine Abrams, Moherndran Archary, Adrie Bekker, Edmund Capparelli, Angela Colbers, Tim Cressey, Lisa Frigati, Asma Hafiz, Irene Mukui, Martina Penazzato, Natella Rakhmanina, Pablo Rojo, Theodore Ruel, Nadia Sam-Agudu, Nandita Sugandhi, Claire Townsend, Marissa Vicari, Melynda Watkins

Affiliations

¹ HIV Department, WHO, Geneva, Switzerland. Electronic address: penazzatom@who.int.
² HIV Department, WHO, Geneva, Switzerland.
³ Pediatric and Adolescent HIV Program and International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria; Institute of Human Virology and Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
⁵ Department of Paediatrics, University of KwaZulu-Natal, Durban, South Africa.
⁶ Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
⁷ AMS-IRD Research Collaboration, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
⁸ Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, Netherlands.
⁹ ICAP, Columbia University, New York, NY, USA.
¹⁰ Pediatric Infectious Diseases Unit, Hospital 12 de Octubre, Madrid, Spain.
¹¹ School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA; Children's National Hospital, Washington, DC, USA; Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.
¹² Clinton Health Access Initiative, Boston, MA, USA.
¹³ Department of Paediatrics, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.
¹⁴ Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
¹⁵ International AIDS Society, Geneva, Switzerland.
¹⁶ Department of Pediatrics and Clinical Pharmacy, University of California San Diego, La Jolla, CA, USA.
¹⁷ ICAP, Columbia University, New York, NY, USA; Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.

PMID: 35863362
DOI: 10.1016/S2352-3018(22)00101-1

Abstract

Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2-3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.

Publication types

Review

MeSH terms

Adolescent
Anti-Retroviral Agents / therapeutic use
Child
Drug Compounding
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Infant
Infant, Newborn
Poverty
Research

Substances

Anti-Retroviral Agents

Grants and funding

001/WHO_/World Health Organization/International